The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That's a good read Balerno1.
Not as much value added for the Exosomes as I thought there would be - but early days.
Very positive.
Hi Chester
Allenby assessing a fair value of 358p only based on hrpc. http://www.allenbycapital.com/research/research-rene.html
Everything is pointing to a significant change in fortunes for Reneuron and therefore us PI investors.
The stage is now set for either an exosomes deal / deals ( with cash up front please ) on the back of the recent 'Proof of Concept' or that the data in the Ph2a Retinitus Pigmentosa trial as seen by Rene is looking very good.
We have not had any recent updates on the CTX programme being run by Fosun Pharma, I am presuming that by now they have actually achieved the necessary approvals to start the CTX trials in China.
Chester.
Decent director buy shows confidence anyway
Thanks Guys - it's good to know I'm not on my own with my thinking.
And for those coming into this stock in relative recent times - good luck to you - but I am a long-term holder and admit to being heavily under-water with RENE.
However, I don't know how similar companies compare.
You're not the only one. General compensation is also high.
- The maximum annual bonus that may be payable
in cash is set at 50% of base salary for the Executive Directors. Up to a further 50% of base salary may be awarded, payable in nominal price share options under the Company’s Long-Term Incentive Plan.
- The Company contribution in respect of Executive Directors is currently set at 10% of base
salary.
- A car allowance of £10,000 per annum to each Executive Director.
- The Company paid a living allowance of £47,000 to the Chief Executive Officer pertaining to the relocation of the Group to the Pencoed, South Wales site (how long ago did they relocate!).
In Olav's case, a salary of £301,000 and £154,000 bonus. When you see the size and location of their building, that seems a lot. He must really bring a lot to the table that we don't get to see. Fundraising at 70p is not one of those things.
I agree with you dactions, I have been a share holder for over 4 years now and showing a large loss on my holdings. I would like to have a large option for under £1 per share this would help me lower my break even point.
Am I the only one that thinks the options are too generous at this stage vis a vis the amount that shareholders have supported this company over the years ?
Once we get deals that will bring in millions then the SP will reflect that. Can't be far off now, perhaps even wks. I'm in accumulation mode and will be holding for either the deals to come to the table or a bid from a large player. Either way not long to wait.
Still favour the prospects and potential but tiring of the constant downwards pressure now
That does make sense. The missing apostrophe sent me in to a tiz. Sorry.
Yes AGM was the other month, Clive is referring/quoting back to a post of his from before then, when the new block listing was announced.
I thought the AGM was last month. Interim results due December.
Reference past post 3m share options with conditions which are fair and send out a positive message to the market - past post ‘Now we have new key management in place, the ability to incentivise, with share options to be awarded from this new block, is highly encouraging and is an indication that timing is near for crucial value changes. The terms of an award, I hope, reflect the last two remaining conditions as per those in place for Olav, i.e. clinical trial phase approval and significant deal. The AGM next week should provide us with a more transparent understanding of the progress. It would be most helpful to have a target date for agreements to be concluded as real shareholder value will start to be realised.
Great to see this latest RNS, which should leave us in no doubt that a deal is imminent. reference